Investments
21Portfolio Exits
14About Spectra Capital Management
Spectrum Capital Management is a Registered Investment Advisor focusing on asset allocation as its core investment approach. The strategy provides a well diversified portfolio by allocating assets across major asset classes such as stocks, bonds and cash. The primary investment goal is to create an optimal combination of those asset types subject to expected market returns and risk tolerance constraints.
Want to inform investors similar to Spectra Capital Management about your company?
Submit your Analyst Briefing to get in front of investors, customers, and partners on CB Insights’ platform.
Spectra Capital Management Investments
21 Investments
Spectra Capital Management has made 21 investments. Their latest investment was in Synvista Therapeutics as part of their Unattributed VC - IV on April 4, 2006.
Spectra Capital Management Investments Activity
Date | Round | Company | Amount | New? | Co-Investors | Sources |
|---|---|---|---|---|---|---|
4/17/2006 | Unattributed VC - IV | Synvista Therapeutics | $2.59M | Yes | ||
3/17/2006 | Unattributed VC | Cellectar Biosciences | $15.06M | Yes | ADAR Investment Management, Advantage Capital, Alpha Capital Partners, AS Capital Partners, BAM Elevate, Beacon Fund Advisors, DKR Capital, Downsview Capital, EagleRock Capital Management, Enable Capital Management, Fursa Alternative Strategies, Hudson Bay Capital Management, Iroquois Capital Group, N.I.R. Group, Nite Capital Management, SDS Capital Partners, SF Capital Group, Spectra Capital Management, Sunrise Equity Partners, TCMP3 Capital, Visium Asset Management, and WhiteRock Partners | |
10/14/2005 | PIPE - II | eMagin | $9.14M | Yes | ||
12/23/2004 | Unattributed VC - III | |||||
11/24/2004 | Unattributed VC - III |
Date | 4/17/2006 | 3/17/2006 | 10/14/2005 | 12/23/2004 | 11/24/2004 |
|---|---|---|---|---|---|
Round | Unattributed VC - IV | Unattributed VC | PIPE - II | Unattributed VC - III | Unattributed VC - III |
Company | Synvista Therapeutics | Cellectar Biosciences | eMagin | ||
Amount | $2.59M | $15.06M | $9.14M | ||
New? | Yes | Yes | Yes | ||
Co-Investors | ADAR Investment Management, Advantage Capital, Alpha Capital Partners, AS Capital Partners, BAM Elevate, Beacon Fund Advisors, DKR Capital, Downsview Capital, EagleRock Capital Management, Enable Capital Management, Fursa Alternative Strategies, Hudson Bay Capital Management, Iroquois Capital Group, N.I.R. Group, Nite Capital Management, SDS Capital Partners, SF Capital Group, Spectra Capital Management, Sunrise Equity Partners, TCMP3 Capital, Visium Asset Management, and WhiteRock Partners | ||||
Sources |
Spectra Capital Management Portfolio Exits
14 Portfolio Exits
Spectra Capital Management has 14 portfolio exits. Their latest portfolio exit was eMagin on May 17, 2023.
Date | Exit | Companies | Valuation Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model. | Acquirer | Sources |
|---|---|---|---|---|---|
5/17/2023 | Acq - Pending | 5 | |||
6/8/2015 | Acq - P2P | 1 | |||
6/21/2012 | Acquired | ||||
Date | 5/17/2023 | 6/8/2015 | 6/21/2012 | ||
|---|---|---|---|---|---|
Exit | Acq - Pending | Acq - P2P | Acquired | ||
Companies | |||||
Valuation | |||||
Acquirer | |||||
Sources | 5 | 1 |
Discover the right solution for your team
The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.